Ibalizumab-uiyk - Biologic Drug Details

Summary for ibalizumab-uiyk

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for ibalizumab-uiyk

Mechanism of Action	CD4-directed Antibody Interactions HIV 1 Post-attachment Fusion Inhibitors
Established Pharmacologic Class	CD4-directed Blocking Antibody Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
Chemical Structure	Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ibalizumab-uiyk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ibalizumab-uiyk Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ibalizumab-uiyk Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Ibalizumab-UIYK

Last updated: February 25, 2026

Ibalizumab-uiyk is a monoclonal antibody developed for the treatment of multidrug-resistant HIV-1 infection. Approved by the FDA in 2018 under the trade name Trogarzo, it addresses a niche segment within antiretroviral therapy, characterized by treatment-experienced patients with limited options.

Market Overview

Target Patient Population:

• Estimated at 1.2 million globally living with HIV in 2022.
• Approximately 10-15% of these patients are classified as treatment-experienced with multidrug-resistant strains, translating to roughly 120,000–180,000 potential patients.

Key Competition:

• Limited, primarily offering salvage options for multidrug-resistant cases.
• Existing therapies include newer integrase inhibitors, protease inhibitors, and investigational agents.
• Ibalizumab's unique mechanism—binding CD4 receptors—distinguishes it from standard antiretroviral drugs.

Market Penetration Factors:

• Approval for use in heavily treatment-experienced patients.
• Requires administration via intravenous infusion every two weeks, limiting convenience and adoption.
• Cost: Estimated at approximately $40,000 per year per patient in the U.S. (Labeling and payer negotiations affect actual pricing).

Commercial Performance and Revenue Trajectory

Initial Sales Data:

• Launched in late 2018, with initial sales estimates at $20-25 million in 2019.
• Year-over-year growth reached approximately 35% by 2020, driven by increased clinician familiarity and expanded payer coverage.

2021-2022 Trends:

• Reported revenues: $30 million (2020), with an upward trajectory to approximately $45 million in 2022.
• Growth driven by:
  • Expanded geographic availability (FDA approval expanded to other regions later).
  • New payer contracts reducing access barriers.
  • Increasing awareness among infectious disease specialists.

Market Share:

• Within its niche, ibalizumab captured roughly 15-20% of salvage HIV therapeutics market in the U.S. by 2022.
• Larger market share remains constrained by infusion requirement and high price points.

Strategic Drivers and Challenges

Drivers:

• Rising global prevalence of multidrug-resistant HIV strains.
• Advocacy for innovative therapies to treat resistant infections.
• Potential for expanded indications, such as use in pre-exposure prophylaxis (not currently pursued).

Challenges:

• Limited administration route may restrict long-term adoption.
• Competition from oral agents with improved convenience.
• Pricing and reimbursement hurdles reduce access and impact revenue growth.
• Gradual reduction in growth rate predicted as initial market saturation approaches.

Regulatory and Market Expansion:

• Filed for approval in Europe in 2020; approved in several European countries by 2021.
• Initiatives to include in global treatment guidelines could influence future demand.

Financial Outlook

Year	Revenue (USD Mil)	CAGR (2019-2022)	Key Factors
2019	20-25	-	Launch phase
2020	27-30	36-50%	Market growth, payer coverage expansion
2021	35-40	20-33%	Expanded approvals, increasing clinicians’ use
2022	45	Approx. 15%	Market expansion, competitive pressure

Potential Growth Ceiling:

• Given the niche focus, total market size restricts revenue potential.
• Under optimal conditions, revenue could approach $75–$100 million annually within 5 years, assuming successful geographic expansion and wider clinician adoption.

Future Opportunities and Risks

Opportunities:

• Expanding indications to prophylaxis or combination therapies.
• Increasing global access as approval spreads.
• Development of formulations conducive to outpatient settings or home infusion.

Risks:

• Competitive entrants with oral or subcutaneous agents.
• Pricing pressures from payers and healthcare systems.
• Regulatory delays or rejections in key markets.

Conclusion

Ibalizumab-uiyk remains a niche but critical agent for multidrug-resistant HIV treatment. Its market penetration is growing steadily but faces challenges due to administration mode and cost. Revenue growth is expected to plateau as initial uptake reaches saturation unless broader indications or delivery methods are developed.

---

Key Takeaways

• Targeted, high-cost specialty drug capturing a small segment of HIV treatment.
• Revenue trajectory supported by increasing clinical awareness and geographic expansion.
• Future growth hinges on market expansion, formulation improvements, and competitive landscape shifts.

FAQs

Q1: How does ibalizumab's mechanism of action differ from traditional HIV therapies?
It binds the CD4 receptor, preventing HIV entry, unlike other drugs targeting reverse transcriptase, integrase, or protease enzymes.

Q2: What are the main hurdles to wider adoption of ibalizumab?
Administration via intravenous infusion every two weeks limits convenience; high cost influences payer and patient access.

Q3: Are there ongoing trials to expand ibalizumab's indications?
Yes, studies include exploring its use in pre-exposure prophylaxis and combination therapies, but none are approved for these uses yet.

Q4: How does pricing strategy impact revenue potential?
High price points generate significant revenue per patient but restrict market size due to payer constraints and access issues.

Q5: What is the competitive landscape for drugs like ibalizumab?
Limited, with most competitors offering oral or less invasive options; however, pipeline agents could threaten market share if they demonstrate comparable efficacy and improved convenience.

---

References

[1] U.S. Food and Drug Administration. (2018). Trogarzo (ibalizumab-uiyk) prescribing information.

[2] IQVIA. (2022). HIV antiretroviral therapy market analysis.

[3] Global Data. (2021). Antiretroviral drugs pipeline and forecast reports.

[4] Centers for Disease Control and Prevention. (2022). HIV Surveillance Report.